Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Bosutinib Pediatric Capsule vs Tablet in Healthy Participants
NCT04549480Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bosutinib in chronic myeloid leukemia (CML) (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Curve From Time Zero to Extrapolated Infinite Time at 6 days and Maximum Observed Plasma Concentration at 6 days. Started Sep 2020; status: completed.
02
Drugs
bosutinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04549480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04549480.